Overview

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
University of Birmingham
Treatments:
Azacitidine